Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $771.12, giving the company a market capitalization of 82.16B. It carries a P/E multiple of 18.74 and pays a dividend yield of 46.1%.
During the trading session on 2026-04-02, Regeneron(REGN) shares reached a daily high of $771.12 and a low of $771.12. At a current price of $771.12, the stock is 0.0% higher than the low and still 0.0% under the high.
Trading activity shows a volume of 232, compared to an average daily volume of 646.66K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sh...
Piper Sandler has initiated Regeneron Pharmaceuticals (REGN) at overweight saying that it expects continued growth in Dupixent (dupilumab) sales as well as "sev...
Analyst ratings
77%
of 31 ratingsMore REGN News
Truist lowered the firm’s price target on Regeneron (REGN) to $801 from $818 and keeps a Buy rating on the shares. 2026 is critical for Eylea at this stage of t...
Wondering whether Regeneron Pharmaceuticals at around US$749 a share still offers value or is already pricing in its strengths? This breakdown focuses squarely...
Explore the exciting world of Regeneron Pharmaceuticals (NASDAQ: REGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out t...
Regeneron Pharmaceuticals (REGN) is back in focus after Japan’s Ministry of Health, Labour and Welfare approved Dupixent for adults with moderate to severe bull...
AstraZeneca reported that its antibody drug tozorakimab succeeded in two Phase 3 trials in chronic obstructive pulmonary disease (COPD), targeting a broad COPD...
Key Points The company is slowly recovering from recent headwinds. It could perform well through the next five to 10 years. 10 stocks we like better than Reg...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.